This preview shows pages 1–2. Sign up to view the full content.
This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: Treatment of Parkinsonism With Levodopa Melvin D. Yahr, MD; Roger C. Duvoisin, MD; Myrna J. Schear, MD; Robert E. Barrett, MD; and Margaret M. Hoehn, MD, New York Some turn this sickness yet might take, Even yet. But he: "What drugcan make A wither'd palsy cease to shake?" "The Two Voices" \p=m-\Tennyson1833 FOR MORE than a century, the treat- ment of parkinsonism has relied on a vari- ety of compounds whose limited therapeutic efficacy depend upon their central parasym- patholytic effects. The shortcomings of these agents, notably their inability to com - pletely reverse the signs and symptoms o r materially alter the progressive disabling n a - ture of the disorder and the high incidence of disturbing side effects, are well appreciat- ed. Under the most optimal circumstances, the best that can be expected from their judicious administration is a 20% reduction in the severity of symptoms with a modest improvement of functional capacity. The demonstration within the past decade of the presence of dopamine in the brain localized chiefly in the striatum and substantia nigra1,2 and the subsequent discovery of its depletion in parkinsonism3,4 and in labora- tory animals following nigral lesions56 have provided the rationale for new therapeutic approaches to parkinsonism. Among the several means considered for correcting the dopamine deficiency, the administration of levodopa, the immediate precursor of dopa mine, has proved, thus far, the most effective, and w e believe it to represent a major ad v a n c e in the treatment of parkinsonism. The initial observations o n the effects of levodopa in parkinsonism were made with single relatively small oral o r parenteral doses. Using a technique previously em ployed by Degkwitz,7 Birkmayer and Hornykiewicz8 administered doses of the order of 25 to 150 mg by slow intravenous injection and observed improvements of gait, speech, and bodily movement, which they interpreted as a decrease of akinesia. Tremor and rigidity did not appear to be significantly influenced. The "dopa effekt," as it w as termed, reached its maximum in two to three hours and persisted to a lesser extent for 24 hours o r longer. Barbeau,910 utilizing oral administration of 200 mg of levodopa in six patients, noted improve ments in the performance of specific tasks of motor function which he interpreted as reduction of rigidity. Tremor w as worsened in one case and remained unchanged in the remainder. Subsequently, Friedhoff et al,11 Gerstenbrand et al,12 Umbach and Bau mann,13 and others1415 reported essentially similar results using small oral o r parenter al doses of levodopa. Birkmayer and Hornykiewicz16 extended their studies and developed a therapeutic regimen in which slow intravenous injec tions of levodopa repeated two o r three Submitted for publication May 7, 1969; accepted June 6....
View Full Document
This note was uploaded on 04/05/2010 for the course MCB 167 taught by Professor Feldman during the Spring '10 term at University of California, Berkeley.
- Spring '10